Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biogen/Elan Seek First-Line Claim For Tysabri In JCV-Negative MS Patients

Jan 16 2013

• By Sue Sutter

Related Content

Biogen Reports Progress In Late-Stage Programs, Plus Some Bumps In The Road

Oct 25 2012

<em>Tysabri’s</em> PML Risk Quantified In Revised Label; Can Added Certainty Add Scripts?

Jan 23 2012

FDA Re-Approves Tysabri, Recommends Second-Line Use

Jun 05 2006

Related Companies

Biogen, Inc.

Elan Corporation

Quest Diagnostics Incorporated

Additional Topics

United States Europe Regulation BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window